Jun. 10 at 7:03 PM
$RNAZ The present market cap of this company is about
$110 million. This figure correctly includes all of the conversion of the preferred shares issued to CK. These shares are effectively regular common shares in the count, and the Street obviously knows this. At this market cap with a successful P1 and commencing P2 for a revolutionary cancer platform, the company is fairly priced. However, this statement ignores the fact that the company received a P3 ready vaccine drug from CK also, which drug is arguably worth another
$250 million. Hence, the stock is cheap, but the cap is not the farsical
$5 million market cap that naive retail investors and manipulative shorters like MBR60 represents the stock to be. Be smart, always count all shares, options, warrants, and convertible instruments as shares outstanding. That is what the Street does, and the Street trades accordingly.
